Turinabol (Oral Turinabol, OT, Tbol) is a derivative of Dianabol with an added 4-chloro modification that eliminates aromatization and reduces androgenic activity. Developed in East Germany in the 1960s for their state-sponsored doping program, it is known for producing slow, steady, lean gains without water retention. It is often described as a "milder Dianabol" with a more favorable side effect profile.
Notes
Turinabol occupies a unique niche as a "slow and steady" oral that provides lean gains without estrogenic sides. It is most effective when used as a complement to injectable compounds rather than as a standalone mass-builder. The 4-chloro modification that prevents aromatization also makes it virtually undetectable on standard drug panels until advanced long-term metabolite testing was developed. Turinabol is valued by athletes who need consistent performance improvement without dramatic weight or water gain. Cycles can be run for 6-8 weeks with moderate hepatic impact. It is one of the best orals for "athletic enhancement" (speed, power, recovery) as opposed to pure bodybuilding mass gain.
Turinabol is structurally a hybrid of Dianabol (methandrostenolone) and clostebol (4-chlorotestosterone). The 4-chloro substitution on the A-ring prevents the aromatase enzyme from binding, completely eliminating estrogenic conversion. It retains the c17-alpha alkylation for oral bioavailability and the C1-2 double bond from Dianabol. Its anabolic rating is approximately 54 (relative to testosterone at 100) with an androgenic rating of 6, making it one of the lowest androgenic AAS available. Turinabol moderately enhances protein synthesis and nitrogen retention. Like Winstrol, it has a significant effect on lowering SHBG, increasing the bioavailability of co-administered testosterone and other AAS. Its low androgenic profile makes it one of the few oral AAS with a reasonable safety margin for female athletes at very low doses (5-10mg/day).
Turinabol is well absorbed orally with an estimated bioavailability of 90%+ due to c17-alpha alkylation. The terminal half-life of approximately 16 hours is notably longer than Dianabol (4-6 hours) and allows for once-daily dosing. Peak plasma levels occur within 1-3 hours. Hepatic metabolism produces several metabolites, including the long-term metabolite (4-chloro-18-nor-17beta-hydroxymethyl,17alpha-methyl-androsta-1,4,13-trien-3-one) that can be detected in urine for 12+ months using IRMS (isotope ratio mass spectrometry) testing. Standard hepatic conjugation and excretion pathways apply. The moderate hepatotoxic burden is proportional to its structural similarity to Dianabol.
Typical Dose
30-40mg/day (beginner), 40-60mg/day (intermediate), 60-80mg/day (advanced)
Frequency
Once daily or split into 2 doses; the long half-life supports once-daily dosing
Administration
Oral (tablet)
Half-Life
16 hours
Contraindications
Begin PCT 1-2 days after the last Turinabol dose (if no long-ester injectables). If combined with injectable testosterone, follow the injectable PCT timeline. Standard PCT: Nolvadex 20mg/day for 4-6 weeks, or Clomid 50mg/day for 3 weeks then 25mg/day for 2 weeks. Turinabol is moderately suppressive; recovery is generally straightforward with standard protocols. Liver support (NAC 1200mg/day) for 3-4 weeks post-cycle.